WO2009117144A1 - Composés benzazépines - Google Patents

Composés benzazépines Download PDF

Info

Publication number
WO2009117144A1
WO2009117144A1 PCT/US2009/001767 US2009001767W WO2009117144A1 WO 2009117144 A1 WO2009117144 A1 WO 2009117144A1 US 2009001767 W US2009001767 W US 2009001767W WO 2009117144 A1 WO2009117144 A1 WO 2009117144A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
deuterium
compounds
composition
disease
Prior art date
Application number
PCT/US2009/001767
Other languages
English (en)
Other versions
WO2009117144A9 (fr
Inventor
Julie F. Liu
Rose A. Persichetti
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of WO2009117144A1 publication Critical patent/WO2009117144A1/fr
Publication of WO2009117144A9 publication Critical patent/WO2009117144A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • Conivaptan also known as [1 ,1 '-biphenyl]-2-carboxamide, ⁇ V-[4-[(4,5- dihydro-2- methylimidazo[4,5 ⁇ i][l]benzazepin-6(lH)-yl)carbonyl]phenyl]-,monohydrochloride, acts as a dual inhibitor of arginine vasopressin (AVP) through binding at the Vi A and V 2 receptors.
  • AVP also known as anti-diuretic hormone (ADH)
  • ADH anti-diuretic hormone
  • Conivaptan is currently approved for euvolemic and hypervolemic hyponatremia in hospitalized patients as an IV formulation.
  • the oral formulation is currently undergoing clinical trials for the treatment of euvolemic and hypervolemic hyponatremia.
  • Ml the product of hydroxylation to the imidazo-methyl-group
  • M2 the product of hydroxylation to the 4-methylene position of the benzazepine ring
  • M4 the product resulting from hydroxylation at both aforementioned sites
  • M7 the product of oxidative de-amination resulting in the benzazepine-cleaved carboxylic acid
  • the most common adverse reactions reported with conivaptan administration include but are not limited to, infusion site reactions (occurring in 73% and 63% of subjects treated with conivaptan 20 mg/day and 40 mg/day, respectively), diarrhea, vomiting, peripheral edema, pyrexia, hypokalemia, hyponatremia, headache, hypertension, and orthostatic hypotension. (See FDA label for vaprisol at http : //www. fda. go v/cder) .
  • This invention relates to novel compounds that are benzazepines derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel benzazepines derivatives that are derivatives of conivaptan.
  • This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual antagonist of the arginine vasopressin (AVP) Vj A and the V 2 receptors, such a conivaptan.
  • AVP arginine vasopressin
  • ameliorate and “treat” are used interchangeably and include both therapeutic treatment and prophylactic treatment (reducing the likelihood of development). Both terms mean decrease, suppress, attenuate, diminish, arrest, or stabilize the development or progression of a disease (e.g., a disease or disorder delineated herein), lessen the severity of the disease or improve the symptoms associated with the disease.
  • a disease e.g., a disease or disorder delineated herein
  • Disease means any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
  • any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
  • a position is designated specifically as “H” or “hydrogen”
  • the position is understood to have hydrogen at its natural abundance isotopic composition.
  • a position is designated specifically as “D” or “deuterium”
  • the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 50.1% incorporation of deuterium).
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a compound of this invention has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3
  • isotopologue refers to a species that differs from a specific compound of this invention only in the isotopic composition thereof.
  • a compound represented by a particular chemical structure containing indicated deuterium atoms will also contain lesser amounts of isotopologues having hydrogen atoms at one or more of the designated deuterium positions in that structure.
  • the relative amount of such isotopologues in a compound of this invention will depend upon a number of factors including the isotopic purity of deuterated reagents used to make the compound and the efficiency of incorporation of deuterium in the various synthesis steps used to prepare the compound.
  • the relative amount of such isotopologues in toto will be less than 49.9% of the compound. In other embodiments, the relative amount of such isotopologues in toto will be less than 47.5%, less than 40%, less than 32.5%, less than 25%, less than 17.5%, less than 10%, less than 5%, less than 3%, less than 1%, or less than 0.5% of the compound.
  • the invention also provides salts, solvates or hydrates of the compounds of the invention.
  • a salt of a compound of this invention is formed between an acid and a basic group of the compound, such as an amino functional group, or a base and an acidic group of the compound, such as a carboxyl functional group.
  • the compound is a pharmaceutically acceptable acid addition salt.
  • pharmaceutically acceptable refers to a component that is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and other mammals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a “pharmaceutically acceptable salt” means any non-toxic salt that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention.
  • a "pharmaceutically acceptable counterion” is an ionic portion of a salt that is not toxic when released from the salt upon administration to a recipient.
  • Acids commonly employed to form pharmaceutically acceptable salts include inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and phosphoric acid, as well as organic acids such as para- toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, para-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid and acetic acid, as well as related inorganic and organic acids.
  • Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephathalate, sulfonate, xylene sulfonate, phenylacetate, phenyl
  • pharmaceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and especially those formed with organic acids such as maleic acid.
  • hydrate means a compound which further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
  • solvate means a compound which further includes a stoichiometric or non-stoichiometric amount of solvent such as water, acetone, ethanol, methanol, dichloromethane, 2-propanol, or the like, bound by non-covalent intermolecular forces.
  • the compounds of the present invention may contain an asymmetric carbon atom, for example, as the result of deuterium substitution or otherwise.
  • compounds of this invention can exist as either individual enantiomers, or mixtures of the two enantiomers. Accordingly, a compound of the present invention will include both racemic mixtures, and also individual respective stereoisomers that are substantially free from another possible stereoisomer.
  • substantially free of other stereoisomers means less than 25% of other stereoisomers, preferably less than 10% of other stereoisomers, more preferably less than 5% of other stereoisomers and most preferably less than 2% of other stereoisomers, or less than "X"% of other stereoisomers (wherein X is a number between 0 and 100, inclusive) are present.
  • Methods of obtaining or synthesizing an individual enantiomer for a given compound are well known in the art and may be applied as practicable to final compounds or to starting material or intermediates.
  • stable compounds refers to compounds which possess stability sufficient to allow for their manufacture and which maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein
  • Stepoisomer refers to both enantiomers and diastereomers.
  • FDA Food and Drug Administration
  • NDA New Drug Application
  • each Z is independently hydrogen or deuterium; R 1 is CD 3 , CD 2 H, CDH 2 , or CH 3 ; and when R 1 is CH 3 , at least one Z is deuterium.
  • Z I a and Z lb are the same; and Z 2a and Z 2b are the same.
  • Z la and Z lb are deuterium; and Z 2a and Z 2b are hydrogen.
  • Z la and Z lb are hydrogen
  • Z 2a and Z 2b are deuterium.
  • Z la and Z Ib are deuterium
  • the compound is selected from any one of the compounds (Cmpd) set forth in Table 1 (below):
  • any atom not designated as deuterium in any of the embodiments set forth above is present at its natural isotopic abundance.
  • the synthesis of compounds of Formula I can be readily achieved by synthetic chemists of ordinary skill. Relevant procedures and intermediates are disclosed, for instance in: JP 1996198879
  • Such methods can be carried out utilizing corresponding deuterated and optionally, other isotope-containing reagents and/or intermediates to synthesize the compounds delineated herein, or invoking standard synthetic protocols known in the art for introducing isotopic atoms to a chemical structure.
  • deuterated amine IX can be prepared following the general procedures of Boegiin, D. et al. J. Comb. Chem. 2007, 9, 3, 487-500.
  • Commercially-available methylanthranilate II is tosylated with TsCl and pyridine to afford ester III.
  • Ester III is treated with NaH and deuterated halo-ester IV in DMF, followed by treatment with NaH in MeOH and toluene, followed by microwave heating in the presence of HCl, AcOH and aqueous EtOH to afford ketone V.
  • Tsunoda T.; Yamazaki, A.; Mase, T.; Sakamoto, S.
  • bromination of ketone V is achieved via treatment with pyridinium hydrobromide perbromide in chloroform to yield bromoketone VI.
  • Cyclization with deuterated amidine VII in the presence of potassium carbonate in toluene yields tricycle VIII.
  • Deprotection of the nitrogen with H 2 SO 4 affords amine IX.
  • the deuterated acetonitrile reagents may be prepared as described in Anthoni, U.; et al. Journal of Labelled Compounds and Radiopharmaceuticals (1984), 21(4), 375-80. [44] Referring again to Scheme 2, the known Br(CD 2 ) 3 CO 2 Me [T. Tanaka, et al. Journal of Labeled Compounds and Radiopharmaceuticals, 29(6), 667-80; 1991] may be used as halo-ester IV to ultimately provide compounds of Formula I wherein all Z are deuterium.
  • Br(CD 2 ) 3 CO 2 Et may be synthesized from commercially-available Br(CD 2 ) 3 CO 2 H and iodoethane according to the methods of T. Tanaka, et al. Journal of Labeled Compounds and Radiopharmaceuticals, 29(6), 667-80; 1991 and used as halo- ester IV to ultimately provide compounds of Formula I wherein all Z are deuterium.
  • halo- ester IV to ultimately provide compounds of Formula I wherein all Z are deuterium.
  • the invention also provides pyrogen-free compositions comprising an effective amount of a compound of Formula I (e.g., including any of the formulae herein), or a pharmaceutically acceptable salt of said compound; and an acceptable carrier.
  • a composition of this invention is formulated for pharmaceutical use ("a pharmaceutical composition"), wherein the carrier is a pharmaceutically acceptable carrier.
  • the carrier(s) are "acceptable” in the sense of being compatible with the other ingredients of the • formulation and, in the case of a pharmaceutically acceptable carrier, not deleterious to the recipient thereof in an amount used in the medicament.
  • Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphat
  • the solubility and bioavailability of the compounds of the present invention in pharmaceutical compositions may be enhanced by methods well-known in the art.
  • One method includes the use of lipid excipients in the formulation. See “Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs (Drugs and the Pharmaceutical Sciences),” David J. Hauss, ed. Informa Healthcare, 2007; and “Role of Lipid Excipients in Modifying Oral and Parenteral Drug Delivery: Basic Principles and Biological Examples," Kishor M. Wasan, ed. Wiley-Interscience, 2006.
  • Another known method of enhancing bioavailability is the use of an amorphous form of a compound of this invention optionally formulated with a poloxamer, such as LUTROLTM and PLURONICTM (BASF Corporation), or block copolymers of ethylene oxide and propylene oxide. See United States patent 7,014,866; and United States patent publications 20060094744 and 20060079502.
  • compositions of the invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
  • the compound of the formulae herein is administered transdermally (e.g., using a transdermal patch or iontophoretic techniques).
  • Other formulations may conveniently be presented in unit dosage form, e.g., tablets, sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, PA (17th ed. 1985).
  • Such preparative methods include the step of bringing into association with the molecule to be administered ingredients such as the carrier that constitutes one or more accessory ingredients.
  • the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • the compound is administered orally.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets, or tablets each containing a predetermined amount of the active ingredient; a powder or granules; a solution or a suspension in an aqueous liquid or a nonaqueous liquid; an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; packed in liposomes; or as a bolus, etc.
  • Soft gelatin capsules can be useful for containing such suspensions, which may beneficially increase the rate of compound absorption.
  • carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
  • compositions suitable for oral administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; and pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia.
  • compositions suitable for parenteral administration include aqueous and nonaqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit- dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • Such injection solutions may be in the form, for example, of a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed .
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long- chain alcohol diluent or dispersant.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
  • suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well- known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. See, e.g.: Rabinowitz JD and Zaffaroni AC, US Patent 6,803,031, assigned to Alexza Molecular Delivery Corporation.
  • Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, and water.
  • the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyldodecanol, benzyl alcohol, and water.
  • the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches and iontophoretic administration are also included in this invention.
  • Application of the subject therapeutics may be local, so as to be administered at the site of interest.
  • Various techniques can be used for providing the subject compositions at the site of interest, such as injection, use of catheters, trocars, projectiles, pluronic gel, stents, sustained drug release polymers or other device which provides for internal access.
  • the compounds of this invention may be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents, or catheters.
  • an implantable medical device such as prostheses, artificial valves, vascular grafts, stents, or catheters.
  • Suitable coatings and the general preparation of coated implantable devices are known in the art and are exemplified in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Coatings for invasive devices are to be included within the definition of pharmaceutically acceptable carrier, adjuvant or vehicle, as those terms are used herein.
  • the invention provides a method of coating an implantable medical device comprising the step of contacting said device with the coating composition described above. It will be obvious to those skilled in the art that the coating of the device will occur prior to implantation into a mammal.
  • the invention provides a method of impregnating an implantable drug release device comprising the step of contacting said drug release device with a compound or composition of this invention.
  • Implantable drug release devices include, but are not limited to, biodegradable polymer capsules or bullets, non-degradable, diffusible polymer capsules and biodegradable polymer wafers.
  • the invention provides an implantable medical device coated with a compound or a composition comprising a compound of this invention, such that said compound is therapeutically active.
  • the invention provides an implantable drug release device impregnated with or containing a compound or a composition comprising a compound of this invention, such that said compound is released from said device and is therapeutically active.
  • composition of this invention may be painted onto the organ, or a composition of this invention may be applied in any other convenient way.
  • a composition of this invention further comprises a second therapeutic agent.
  • the second therapeutic agent may be selected from any compound or therapeutic agent known to have or that demonstrates advantageous properties when administered with a compound having the same mechanism of action as conivaptan.
  • Such agents include those indicated as being useful in combination with conivaptan, including but not limited to, those described in WO 1999065525, WO
  • the second therapeutic agent is an agent useful in the treatment or prevention of a disease or condition selected from diseases impacted by arginine vasopressin such as heart failure, hyponatremia, syndrome of inappropriate vasopressin secretion (SIADH), hypertension, pulmonary hypertension, renal diseases (nephrosis, nephritis, diabetic nephropathy, chronic or acute renal failure), edema, brain edema, ascites, hepatic cirrhosis, hypokalemia, water metabolism disorder, diabetes, various ischemic diseases, cerebrovascular disease, cyclothymic failure, gastric ulcer, nausea, vomiting, syncope, renal function disorder and the like, sequelae of cerebral infarction, intracerebral bleeding and the like, dysmenorrhea!, vision disorders based on ocular circulatory disorders such as intraocular hypertension and glaucoma, and vision disorders based on ciliary tension such as shortsightedness.
  • a disease or condition selected from diseases impacted by
  • the invention provides separate dosage forms of a compound of this invention and one or more of any of the above-described second therapeutic agents, wherein the compound and second therapeutic agent are associated with one another.
  • association with one another means that the separate dosage forms are packaged together or otherwise attached to one another such that it is readily apparent that the separate dosage forms are intended to be sold and administered together (within less than 24 hours of one another, consecutively or simultaneously).
  • the compound of the present invention is present in an effective amount.
  • effective amount refers to an amount which, when administered in a proper dosing regimen, is sufficient to treat (therapeutically or prophylactically) the target disorder. For example, and effective amount is sufficient to reduce or ameliorate the severity, duration or progression of the disorder being treated, prevent the advancement of the disorder being treated, cause the regression of the disorder being treated, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
  • an effective amount of a compound of this invention can range from about 0.1 mg to about 600 mg per treatment. In more specific embodiments the range is from about 1 mg to 300 mg, or from about 2 mg to 120 mg, or most specifically from about 10 mg to about 60 mg per treatment.
  • Treatment typically is administered as a continuous infusion for 1-4 days in the case of the IV formulation of conivaptan, or is administered twice daily in the case of the oral formulation of conivaptan. Duration of treatment is not to exceed 4 days.
  • Effective doses will also vary, as recognized by those skilled in the art, depending on the diseases treated, the severity of the disease, the route of administration, the sex, age and general health condition of the patient, excipient usage, the possibility of co- usage with other therapeutic treatments such as use of other agents and the judgment of the treating physician. For example, guidance for selecting an effective dose can be determined by reference to the prescribing information for conivaptan.
  • an effective amount of the second therapeutic agent is between about 20% and 100% of the dosage normally utilized in a monotherapy regime using just that agent. Preferably, an effective amount is between about 70% and 100% of the normal monotherapeutic dose.
  • the normal monotherapeutic dosages of these second therapeutic agents are well known in the art.
  • the invention provides a method of inhibiting the activity of arginine vasopressin (AVP) through binding at its V I A and V 2 receptors in a cell, comprising contacting a cell with one or more compounds of Formula I herein.
  • AVP arginine vasopressin
  • the invention provides a method of treating a disease that is beneficially treated by conivaptan in a patient in need thereof comprising the step of administering to said patient an effective amount of a compound or a composition of this invention.
  • diseases are well known in the art and are disclosed in, but not limited to the following patents and published applications: WO 1995003305, WO 1999038533, US 2002128259, and WO 2005039565.
  • Such diseases include, but are not limited to, heart failure, hyponatremia, syndrome of inappropriate vasopressin secretion (SIADH), hypertension, pulmonary hypertension, renal diseases (nephrosis, nephritis, diabetic nephropathy, chronic or acute renal failure), edema, brain edema, ascites, hepatic cirrhosis, hypokalemia, water metabolism disorder, diabetes, various ischemic diseases, cerebrovascular disease, cyclothymic failure, gastric ulcer, nausea, vomiting, syncope, renal function disorder and the like, sequelae of cerebral infarction, intracerebral bleeding and the like, dysmenorrhea, vision disorders based on ocular circulatory disorders such as intraocular hypertension and glaucoma, and vision disorders based on ciliary tension such as shortsightedness.
  • SIADH inappropriate vasopressin secretion
  • the method of this invention is used to treat a disease or condition selected from euvolemic and hypervolemic hyponatremia.
  • Methods delineated herein also include those wherein the patient is identified as in need of a particular stated treatment. Identifying a patient in need of such treatment can be in the judgment of a patient or a health care professional and can be subjective (e.g. opinion) or objective (e.g. measurable by a test or diagnostic method).
  • any of the above methods of treatment comprises the further step of co-administering to said patient one or more second therapeutic agents.
  • the choice of second therapeutic agent may be made from any second therapeutic agent known to be useful for co-administration with conivaptan.
  • the choice of second therapeutic agent is also dependent upon the particular disease or condition to be treated. Examples of second therapeutic agents that may be employed in the methods of this invention are those set forth above for use in combination compositions comprising a compound of this invention and a second therapeutic agent.
  • co-administered means that the second therapeutic agent may be administered together with a compound of this invention as part of a single dosage form (such as a composition of this invention comprising a compound of the invention and an second therapeutic agent as described above) or as separate, multiple dosage forms. Alternatively, the additional agent may be administered prior to, consecutively with, or following the administration of a compound of this invention. In such combination therapy treatment, both the compounds of this invention and the second therapeutic agent(s) are administered by conventional methods.
  • composition of this invention comprising both a compound of the invention and a second therapeutic agent, to a patient does not preclude the separate administration of that same therapeutic agent, any other second therapeutic agent or any compound of this invention to said patient at another time during a course of treatment.
  • Effective amounts of these second therapeutic agents are well known to those skilled in the art and guidance for dosing may be found in patents and published patent applications referenced herein, as well as in Wells et al., eds., Pharmacotherapy Handbook, 2nd Edition, Appleton and Lange, Stamford, Conn. (2000); PDR Pharmacopoeia, Tarascon Pocket Pharmacopoeia 2000, Deluxe Edition, Tarascon Publishing, Loma Linda, Calif. (2000), and other medical texts. However, it is well within the skilled artisan's purview to determine the second therapeutic agent's optimal effective-amount range.
  • the effective amount of the compound of this invention is less than its effective amount would be where the second therapeutic agent is not administered. In another embodiment, the effective amount of the second therapeutic agent is less than its effective amount would be where the compound of this invention is not administered. In this way, undesired side effects associated with high doses of either agent may be minimized. Other potential advantages (including without limitation improved dosing regimens and/or reduced drug cost) will be apparent to those of skill in the art.
  • the invention provides the use of a compound of Formula I alone or together with one or more of the above-described second therapeutic agents in the manufacture of a medicament, either as a single composition or as separate dosage forms, for treatment or prevention in a patient of a disease, disorder or symptom set forth above.
  • Another aspect of the invention is a compound of Formula I for use in the treatment or prevention in a patient of a disease, disorder or symptom thereof delineated herein.
  • kits for use to treat euvolemic and hypervolemic hyponatremia comprise (a) a pharmaceutical composition comprising a compound of Formula I or a salt thereof, wherein said pharmaceutical composition is in a container; and (b) instructions describing a method of using the pharmaceutical composition to treat euvolemic and hypervolemic hyponatremia.
  • the container may be any vessel or other sealed or sealable apparatus that can hold said pharmaceutical composition. Examples include bottles, ampules, divided or multi -chambered holders bottles, wherein each division or chamber comprises a single dose of said composition, a divided foil packet wherein each division comprises a single dose of said composition, or a dispenser that dispenses single doses of said composition.
  • the container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
  • a pharmaceutically acceptable material for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule.
  • the container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form. For example, tablets may be contained in a bottle, which is in turn
  • kits of this invention may also comprise a device to administer or to measure out a unit dose of the pharmaceutical composition.
  • a device to administer or to measure out a unit dose of the pharmaceutical composition may include an inhaler if said composition is an inhalable composition; a syringe and needle if said composition is an injectable composition; a syringe, spoon, pump, or a vessel with or without volume markings if said composition is an oral liquid composition; or any other measuring or delivery device appropriate to the dosage formulation of the composition present in the kit.
  • kits of this invention may comprise in a separate vessel of container a pharmaceutical composition comprising a second therapeutic agent, such as one of those listed above for use for co-administration with a compound of this invention.
  • a pharmaceutical composition comprising a second therapeutic agent, such as one of those listed above for use for co-administration with a compound of this invention.
  • Microsomal Assay Human liver microsomes (20 mg/mL) are obtained from Xenotech, LLC (Lenexa, KS). ⁇ -nicotinamide adenine dinucleotide phosphate, reduced form (NADPH), magnesium chloride (MgCl 2 ), and dimethyl sulfoxide (DMSO) are purchased from Sigma-Aldrich. The incubation mixtures are prepared according to Table 2: Table 2. Reaction Mixture Composition for Human Liver Microsome Study
  • SUPERSOMESTM Assay Various human cytochrome P450-specific SUPERSOMESTM are purchased from Gentest (Woburn, MA, USA). A l.O raL reaction mixture containing 25 pmole of SUPERSOMESTM, 2.OmM NADPH, 3.OmM MgCl, and l ⁇ M of a compound of Formula I in 10OmM potassium phosphate buffer (pH 7.4) is incubated at 37 0 C in triplicate. Positive controls contain 1 ⁇ M of dimebolin instead of a compound of formula I. Negative controls used Control Insect Cell Cytosol (insect cell microsomes that lacked any human metabolic enzyme) purchased from GenTest (Woburn, MA, USA).
  • Aliquots (50 ⁇ L) are removed from each sample and placed in wells of a multi-well plate at various time points (e.g., 0, 2, 5, 7, 12, 20, and 30 minutes) and to each aliquot is added 50 ⁇ L of ice cold acetonitrile with 3 ⁇ M haloperidol as an internal standard to stop the reaction.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention porte sur de nouveaux composés qui sont des dérivés de benzazépine et sur leurs sels pharmaceutiquement acceptables. Plus spécifiquement, cette invention porte sur de nouveaux dérivés de benzazépine qui sont des dérivés du conivaptan. Cette invention porte également sur des compositions comprenant un ou plusieurs composés de cette invention et un support, ainsi que sur l'utilisation des composés décrits et compositions décrites dans des procédés de traitement de maladies et d'états qui sont traités de façon utile par l'administration d'un antagoniste double des récepteurs V1a et V2 de l'arginine vasopressine (AVP), tel qu'un conivaptan.
PCT/US2009/001767 2008-03-20 2009-03-20 Composés benzazépines WO2009117144A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7007508P 2008-03-20 2008-03-20
US61/070,075 2008-03-20

Publications (2)

Publication Number Publication Date
WO2009117144A1 true WO2009117144A1 (fr) 2009-09-24
WO2009117144A9 WO2009117144A9 (fr) 2009-12-30

Family

ID=40823133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/001767 WO2009117144A1 (fr) 2008-03-20 2009-03-20 Composés benzazépines

Country Status (1)

Country Link
WO (1) WO2009117144A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052519A1 (fr) 2009-10-26 2011-05-05 大塚製薬株式会社 Composé de benzazépine
CN103204856A (zh) * 2013-04-15 2013-07-17 公安部物证鉴定中心 氘代阿普唑仑及其制备方法
WO2019141575A1 (fr) 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Assistance dans le cadre du traitement de l'insuffisance cardiaque

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069295A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched conivaptan

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069295A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched conivaptan

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1 January 1985 (1985-01-01), pages 1 - 40, XP009086953, ISSN: 0065-2490 *
KUSHNER DJ ET AL: "Pharmacological uses and perspectives of heavy water and deuterated compounds", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, OTTAWA, ONT, CA, vol. 77, no. 2, 1 February 1999 (1999-02-01), pages 79 - 88, XP009086918 *
MANNING MAURICE ET AL: "Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.", PROGRESS IN BRAIN RESEARCH 2008, vol. 170, 2008, pages 473 - 512, XP009119820, ISSN: 1875-7855 *
RAMPE D ET AL: "Deuterated analogs of verapamil and nifedipine. Synthesis and biological activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 28, no. 3, 1 January 1993 (1993-01-01), pages 259 - 263, XP023871274, ISSN: 0223-5234, [retrieved on 19930101] *
VERBALIS ET AL: "Hyponatremia Treatment Guidelines 2007: Expert Panel Recommendations", AMERICAN JOURNAL OF MEDICINE, XX, XX, vol. 120, no. 11, 2 November 2007 (2007-11-02), pages S1 - S21, XP022324624, ISSN: 0002-9343 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011052519A1 (fr) 2009-10-26 2011-05-05 大塚製薬株式会社 Composé de benzazépine
US8940727B2 (en) 2009-10-26 2015-01-27 Otsuka Pharmaceutical Co., Ltd. Benzazepine compound
CN104829531A (zh) * 2009-10-26 2015-08-12 大塚制药株式会社 苯并氮杂*化合物
CN103204856A (zh) * 2013-04-15 2013-07-17 公安部物证鉴定中心 氘代阿普唑仑及其制备方法
WO2019141575A1 (fr) 2018-01-16 2019-07-25 Bayer Aktiengesellschaft Assistance dans le cadre du traitement de l'insuffisance cardiaque

Also Published As

Publication number Publication date
WO2009117144A9 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
US8552008B2 (en) Deuterated 3-(dihydro-1H-pyrazolo[4,3-D]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
EP2190841B1 (fr) Dérivés d'oxazolidinones substituées
US8921366B2 (en) Substituted triazolo-pyridazine derivatives
US8084464B2 (en) Tetrahydroisoquinoline derivatives
US8198305B2 (en) 1,2-benzisoxazol-3-yl compounds
WO2009045476A1 (fr) Dérivés de pyrimidinedione
US7932235B2 (en) Triazolyl tropane derivatives
US7820666B2 (en) Tetrahydrotriazolopyrazine derivatives and uses thereof
US20100004340A1 (en) Naphthyl(ethyl) acetamides
US20110117084A1 (en) Vandetanib derivatives
US20110313004A1 (en) Deuterated pyridinones
EP2125717B1 (fr) Derives deuteres de silodosin en tant qu'antagonistes de l'adrenorecepteur alpha ia
WO2009117144A1 (fr) Composés benzazépines
WO2009158005A1 (fr) Composés à base de benzazépinone
US20080280927A1 (en) 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20090270425A1 (en) 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20110129549A1 (en) Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
WO2009140279A2 (fr) Composés de sulfonylurée
US20100137215A1 (en) Novel tetrahydro-1h-pyrido[4,3-b]indoles
WO2009099620A1 (fr) Dérivés de 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzènesulfonamide et procédés d'utilisation
WO2010002451A1 (fr) Dérivés de naphtyridine
WO2009155309A1 (fr) Dérivés substitués de cyanopyrrolidine
WO2009151613A1 (fr) Dérivés d’oxybutynine
WO2010036773A1 (fr) Dérivés déutérisés de l-aryl-2-aminométhylcyclopropane carboxamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09722315

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09722315

Country of ref document: EP

Kind code of ref document: A1